GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Stayble Therapeutics AB (STU:4K4) » Definitions » Forward Dividend Yield %

Stayble Therapeutics AB (STU:4K4) Forward Dividend Yield % : 0.00% (As of May. 28, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Stayble Therapeutics AB Forward Dividend Yield %?

As of today (2024-05-28), the Forward Annual Dividend Yield of Stayble Therapeutics AB is 0.00%.

As of today (2024-05-28), the Trailing Annual Dividend Yield of Stayble Therapeutics AB is 0.00%.

STU:4K4's Forward Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.63
* Ranked among companies with meaningful Forward Dividend Yield % only.

Stayble Therapeutics AB's Dividends per Share for the three months ended in Sep. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Stayble Therapeutics AB's Forward Dividend Yield %

For the Biotechnology subindustry, Stayble Therapeutics AB's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Stayble Therapeutics AB's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Stayble Therapeutics AB's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Stayble Therapeutics AB's Forward Dividend Yield % falls into.



Stayble Therapeutics AB Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Stayble Therapeutics AB  (STU:4K4) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Stayble Therapeutics AB Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Stayble Therapeutics AB's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Stayble Therapeutics AB (STU:4K4) Business Description

Traded in Other Exchanges
Address
Medicinaregatan 8a, Gothenburg, SWE, SE-413 90
Stayble Therapeutics AB is a clinical-stage pharmaceutical company developing STA363, an intradiscally injected formulation against chronic discogenic low back pain. The treatment is aimed at patients whose back pain persists after physiotherapy and analgesics. The injection is given once and the effect is expected to remain throughout the patient's life and requires minimal rehabilitation. The company's injection treatment, STA363, is expected to correct the underlying cause of disc-related low back pain by affecting the two main causative factors namely instability of the disc and prevention of leakage of inflammatory mediators from the disc center.

Stayble Therapeutics AB (STU:4K4) Headlines

No Headlines